226 related articles for article (PubMed ID: 20182713)
1. A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues.
Schroeder RP; Müller C; Reneman S; Melis ML; Breeman WA; de Blois E; Bangma CH; Krenning EP; van Weerden WM; de Jong M
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1386-96. PubMed ID: 20182713
[TBL] [Abstract][Full Text] [Related]
2. Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts.
Schroeder RP; van Weerden WM; Krenning EP; Bangma CH; Berndsen S; Grievink-de Ligt CH; Groen HC; Reneman S; de Blois E; Breeman WA; de Jong M
Eur J Nucl Med Mol Imaging; 2011 Jul; 38(7):1257-66. PubMed ID: 21431398
[TBL] [Abstract][Full Text] [Related]
3. [99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging.
Nock B; Nikolopoulou A; Chiotellis E; Loudos G; Maintas D; Reubi JC; Maina T
Eur J Nucl Med Mol Imaging; 2003 Feb; 30(2):247-58. PubMed ID: 12552343
[TBL] [Abstract][Full Text] [Related]
4. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours.
Zhang H; Schuhmacher J; Waser B; Wild D; Eisenhut M; Reubi JC; Maecke HR
Eur J Nucl Med Mol Imaging; 2007 Aug; 34(8):1198-208. PubMed ID: 17262215
[TBL] [Abstract][Full Text] [Related]
5. Receptor-binding, biodistribution, dosimetry, and micro-SPECT/CT imaging of 111In-[DTPA(1), Lys(3), Tyr(4)]-bombesin analog in human prostate tumor-bearing mice.
Ho CL; Chen LC; Lee WC; Chiu SP; Hsu WC; Wu YH; Yeh CH; Stabin MG; Jan ML; Lin WJ; Lee TW; Chang CH
Cancer Biother Radiopharm; 2009 Aug; 24(4):435-43. PubMed ID: 19694578
[TBL] [Abstract][Full Text] [Related]
6. Improving radiopeptide pharmacokinetics by adjusting experimental conditions for bombesin receptor-targeted imaging of prostate cancer.
Schroeder RP; De Blois E; De Ridder CM; Van Weerden WM; Breeman WA; de Jong M
Q J Nucl Med Mol Imaging; 2012 Oct; 56(5):468-75. PubMed ID: 23069925
[TBL] [Abstract][Full Text] [Related]
7. PEGylation of (99m)Tc-labeled bombesin analogues improves their pharmacokinetic properties.
Däpp S; García Garayoa E; Maes V; Brans L; Tourwé DA; Müller C; Schibli R
Nucl Med Biol; 2011 Oct; 38(7):997-1009. PubMed ID: 21982571
[TBL] [Abstract][Full Text] [Related]
8. Molecular imaging of gastrin-releasing peptide receptor-positive tumors in mice using 64Cu- and 86Y-DOTA-(Pro1,Tyr4)-bombesin(1-14).
Biddlecombe GB; Rogers BE; de Visser M; Parry JJ; de Jong M; Erion JL; Lewis JS
Bioconjug Chem; 2007; 18(3):724-30. PubMed ID: 17378600
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo evaluation of a 64Cu-labeled NOTA-Bn-SCN-Aoc-bombesin analogue in gastrin-releasing peptide receptor expressing prostate cancer.
Craft JM; De Silva RA; Lears KA; Andrews R; Liang K; Achilefu S; Rogers BE
Nucl Med Biol; 2012 Jul; 39(5):609-16. PubMed ID: 22261146
[TBL] [Abstract][Full Text] [Related]
10. Novel 111In-labelled bombesin analogues for molecular imaging of prostate tumours.
de Visser M; Bernard HF; Erion JL; Schmidt MA; Srinivasan A; Waser B; Reubi JC; Krenning EP; de Jong M
Eur J Nucl Med Mol Imaging; 2007 Aug; 34(8):1228-38. PubMed ID: 17287960
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer.
Richter S; Wuest M; Krieger SS; Rogers BE; Friebe M; Bergmann R; Wuest F
Nucl Med Biol; 2013 Nov; 40(8):1025-34. PubMed ID: 23969085
[TBL] [Abstract][Full Text] [Related]
12. Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CT.
Maina T; Bergsma H; Kulkarni HR; Mueller D; Charalambidis D; Krenning EP; Nock BA; de Jong M; Baum RP
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):964-973. PubMed ID: 26631238
[TBL] [Abstract][Full Text] [Related]
13. MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue.
Rogers BE; Bigott HM; McCarthy DW; Della Manna D; Kim J; Sharp TL; Welch MJ
Bioconjug Chem; 2003; 14(4):756-63. PubMed ID: 12862428
[TBL] [Abstract][Full Text] [Related]
14. Preclinical pharmacokinetic, biodistribution, imaging and therapeutic efficacy of (177)Lu-Labeled glycated bombesin analogue for gastrin-releasing peptide receptor-positive prostate tumor targeting.
Lim JC; Cho EH; Kim JJ; Choi SM; Lee SY; Nam SS; Park UJ; Park SH
Nucl Med Biol; 2015 Mar; 42(3):234-41. PubMed ID: 25498002
[TBL] [Abstract][Full Text] [Related]
15. Peptide receptor imaging of prostate cancer with radiolabelled bombesin analogues.
Schroeder RP; van Weerden WM; Bangma C; Krenning EP; de Jong M
Methods; 2009 Jun; 48(2):200-4. PubMed ID: 19398012
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of a novel ¹¹¹In-labeled bombesin homodimer for improved imaging of GRPR-positive prostate cancer.
Carlucci G; Ananias HJ; Yu Z; Hoving HD; Helfrich W; Dierckx RA; Liu S; de Jong IJ; Elsinga PH
Mol Pharm; 2013 May; 10(5):1716-24. PubMed ID: 23590837
[TBL] [Abstract][Full Text] [Related]
17. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts.
Chen X; Park R; Hou Y; Tohme M; Shahinian AH; Bading JR; Conti PS
J Nucl Med; 2004 Aug; 45(8):1390-7. PubMed ID: 15299066
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
